[ACCESSWIRE]
SCOTTSDALE, AZ / ACCESSWIRE / May 23, 2016 / BioNovelus, Inc. (PINKSHEETS: ONOV) BioNovelus executives President and CEO Jean Ekobo, and CFO, Mark Johnson, will be in Costa Rica the week of May 23, 2016 touring and evaluating five coffee farms participating in a Pilot Test that has revealed CR-10 to be an effective coffee leaf rust killer.
Additionally, BioNovelus has signed a Letter of Intent with a prominent Costa Rican distribution company dedicated to the production and commercialization of agrochemicals, fertilizers, fungicides, seeds and spraying equipment. This company also has expressed an interest in becoming the exclusive importer, distributor and seller of BioNovelus products throughout Central America.
This alliance has the potential to open the Central American market to BioNovelus for its biodegradable biopesticide, CR-10. Costa Rica is fourth in size with 93,800 hectares of coffee plantations in the region. Honduras comes first with 282,500 hectares, followed by Guatemala with 276,500 hectares, El Salvador with 152,200 hectares and Nicaragua with 126,200 hectares.
"Now that the rainy season has started, says Jean Ekobo, we are even more eager to monitor CR-10's performance. The data being collected by the farm cooperative CoopeAgri's is invaluable in proving that our product is effective throughout the entire coffee growing season."
About BioNovelus Inc.
BioNovelus, Inc. (PINKSHEETS: ONOV) is a biotech company that honors the environment with an innovative and cost effective solution to problems associated with food production and water supply.
Additional Information:
For additional information: http://bionovelus.com
Forward-Looking Statements:
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2015 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.
Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company's control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
Contact:
Nathalie Ekobo
Marketing & Communications Director
BioNovelus, Inc.
Skype: bionovelus.inc
+1 602-888-3424
[email protected]
SOURCE: BioNovelus Inc.
